[Form 4] VolitionRX Limited Insider Trading Activity
Rhea-AI Filing Summary
VolitionRx Ltd. (VNRX) – Form 4 filing
On 08/05/2025, President, CEO & Director Cameron John Reynolds purchased 78,125 shares of common stock at $0.64 per share during the company’s registered direct offering (transaction code “P”). The acquisition raises his direct holdings to 2,609,847 shares. Reynolds also controls 1,007,718 shares through Concord International, Inc. and 34,076 shares held by his spouse, bringing his total beneficial ownership to roughly 3.65 million shares. No derivative securities were exercised or sold, and no dispositions were reported.
This insider buy represents an out-of-pocket investment of approximately $50,000, strengthening management’s alignment with shareholders. The shares were obtained via a primary issuance, indicating additional capital raised by the company.
Positive
- None.
Negative
- None.
Insights
TL;DR: CEO invests ~$50k, lifts direct stake to 2.6 M shares; positive insider signal.
The purchase at $0.64 during a registered direct offering shows the CEO committing fresh capital at the same terms as outside investors. Direct ownership grows by 3.1%, while total beneficial control now approaches 3.65 M shares. Insider buying—especially from the chief executive—is often interpreted as confidence in future prospects and can improve market sentiment. No sales or derivative conversions accompany this filing, underscoring a purely additive transaction. Given the modest size relative to float but clear optical value, I view the disclosure as incrementally positive.
TL;DR: New equity issuance dilutes existing holders; overall impact neutral.
While insider participation is welcome, the shares were issued through a registered direct offering, which increases outstanding share count. Unless proceeds are deployed effectively, dilution may offset the benefit of insider confidence. The transaction size—78,125 shares—is small in isolation and unlikely to materially alter control dynamics. Absence of a Rule 10b5-1 plan box suggests a discretionary purchase. Net effect is neutral: positive governance signal balanced by dilution risk.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 78,125 | $0.64 | $50K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- Acquired at the offering price in the registered direct offering of Common Stock by VolitionRx. The shares of common stock are held directly by Concord International, Inc. Mr. Reynolds is the majority shareholder of Concord International, Inc. and shares voting and dispositive control over the shares of common stock held by Concord International, Inc.
